After recent restrictions on selling patented GLP-1 weight-loss drugs, telehealth startups are shifting to liraglutide, a once-popular medication that mimics the effects of newer GLP-1 drugs. Despite its drawbacks, such as needing daily injections, liraglutideâs availability in generic form and lower cost make it appealing. With the FDA's decision to lift shortages on popular GLP-1 drugs, companies like Hims and Olympia Pharmaceuticals are ramping up production and distribution of liraglutide, anticipating increased demand from patients seeking effective weight-loss solutions.
Liraglutide, while less effective than newer GLP-1 drugs, is gaining traction among online clinics as telehealth startups pivot away from patented medications.
The FDA's ruling on GLP-1 drugs has led to a resurgence in liraglutide prescriptions, with telehealth companies eager to meet increasing demand.
Collection
[
|
...
]